Introduction {#Sec1}
============

The prevalence of hypertension rises with age \[[@CR1]--[@CR4]\]. In the US, hypertension occurs in 70.8 % of women and 63.9 % of men 65--74 years of age and 80.1 % of women and 72.1 % of men ≥75 years of age, largely due to increased systolic blood pressure (SBP) \[[@CR1]\]. Individuals over 60 years of age are also the most rapidly growing segment of the US population. By 2025, the worldwide prevalence of hypertension will reach 50.3 % in women and 46.0 % in men 60--69 years of age and 66.8 % in women and 57.1 % in men ≥70 years of age \[[@CR5]\].

Adequately treating hypertension is important since cardiovascular disease risk is doubled with each 7 years of advancing age, 20-mmHg increment in SBP, or 10-mmHg increment in diastolic BP (DBP) \[[@CR6]\]. National Health and Nutrition Examination Survey (NHANES) data indicate that only 53 % of individuals ≥60 years of age have adequate BP control \[[@CR1]\]. In order to achieve adequate BP reduction, many elderly individuals require more than one drug \[[@CR7]\]. If multiple-pill therapies adversely affect therapeutic adherence in this population \[[@CR8], [@CR9]\], many elderly patients with hypertension may benefit from single-pill, multiple-combination therapy \[[@CR5], [@CR10], [@CR11]\].

In the *Tri*ple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hyperte*n*s*i*ve Patien*t*s Stud*y* (TRINITY; ClinicalTrials.gov Identifier: NCT00649389), the triple-combination treatment of olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg reduced both seated DBP (SeDBP) and seated SBP (SeSBP) to a greater degree than the 3 dual-combination treatments, enabling a greater proportion of study participants to reach BP goal (\<140/90 mmHg \[\<130/80 mmHg in participants with diabetes, chronic kidney disease, or chronic cardiovascular disease\]) \[[@CR12]\]. The objective of the current prespecified TRINITY subgroup analysis was to evaluate the efficacy and safety of the OM 40/AML 10/HCTZ 25 mg triple-combination treatment compared with the 3 component dual-combination treatments in participants with hypertension who were \<65 and ≥65 years of age. Within the ≥65 years of age subgroup, efficacy and safety were also summarized for participants ≥75 years of age.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

The detailed TRINITY study design and results of the 12-week randomized phase for the total population have been previously reported \[[@CR12]\]. Briefly, the TRINITY study was a multicenter, double-blind, randomized, parallel-group trial conducted at 317 clinical sites in the US and Puerto Rico. Individuals eligible for randomization were ≥18 years of age with mean seated BP (SeBP) ≥140/100 or ≥160/90 mmHg on 2 consecutive visits off antihypertensive medication. Persons with a recent history (≤6 months) or presence of significant cardiovascular or cerebrovascular disease, coronary artery disease, New York Heart Association class III or IV congestive heart failure, severe renal insufficiency (defined as creatinine clearance \<30 mL/min), or uncontrolled diabetes (defined as hemoglobin A1c \>9 %) were excluded. Individuals with type 1 or type 2 diabetes whose diabetes was controlled for ≥30 days by a stable regimen of diet, insulin, or oral hypoglycemic agents and persons with chronic kidney disease (creatinine clearance ≥30 and ≤60 mL/min) were eligible to participate. The study was conducted in accordance with the institutional review board committee regulations and the Declaration of Helsinki, and written informed consent was obtained from each individual before participation in any study procedures.

Study Design and Procedures {#Sec4}
---------------------------

The study included a 3-week washout period (for participants receiving antihypertensive treatment at screening) followed by a 12-week double-blind treatment period. On day 1, eligible study participants were randomized using an interactive voice response system to a treatment sequence that led to their final treatment assignment (OM 40/AML 10/HCTZ 25 mg \[given as OM 40/HCTZ 25 mg fixed-dose combination plus AML 10 mg given separately\], OM 40/AML 10 mg \[fixed-dose combination\], OM 40/HCTZ 25 mg \[fixed-dose combination\], or AML 10/HCTZ 25 mg \[given separately\]). All participants received dual-combination treatment for 2 weeks, except for a subset of 36 study participants who had not been on antihypertensive medications for at least 3 weeks and who received placebo for 2 weeks (in order to assess the study for non-treatment-associated BP effects). All participants assigned to dual-combination treatment remained on their assigned treatment until week 4. All participants on placebo at week 2 were switched to 1 of the 3 dual-combination treatments from week 2 to week 4. At week 4, participants were either maintained on dual-combination treatment to week 12 or switched to triple-combination treatment with OM 40/AML 10/HCTZ 25 mg until week 12. Study participants were instructed to take all study medication at the same time (±2 h) each day and investigators and study participants remained blinded as to which medication was being administered at any given time \[[@CR12]\].

BP was measured at all study visits during the double-blind treatment period, including day 1 and weeks 2, 4, 6, 8, 10, and 12. BP was measured at all sites using an automated BP monitor (OMRON HEM-705CP, Omron Healthcare, Inc., Bannockburn, Illinois) that produced a printout of each BP assessment with the use of a cuff of appropriate size. Measurements were taken with the patient in a seated position after a 5-min rest. Three BP measurements were obtained at 1-min intervals during each visit \[[@CR12]\].

Efficacy Assessments {#Sec5}
--------------------

The primary efficacy variable was the least squares (LS) mean change from baseline to week 12 in SeDBP in each age subgroup. Secondary efficacy variables included the LS mean change from baseline to week 12 in SeSBP, proportion of study participants reaching SeBP goal (\<140/90 mmHg \[\<130/80 mmHg in study participants with diabetes, chronic kidney disease, or chronic cardiovascular disease\]) at week 12, proportion of study participants achieving SeBP target (\<140/90 mmHg) at week 12 (subgroup post hoc analysis), and the mean change in SeBP from baseline to week 12 in study participants with severe hypertension (SeSBP ≥180 mmHg or SeDBP ≥110 mmHg) at baseline (subgroup post hoc analysis).

Safety Assessments {#Sec6}
------------------

Safety was assessed at all study visits. Safety assessments included physical examinations (including vital signs), 12-lead electrocardiograms, clinical laboratory testing, and adverse events.

Statistical Analysis {#Sec7}
--------------------

The primary efficacy analysis included all study participants who had baseline assessment of SeDBP, received at least 1 dose of study medication, and had at least 1 post-dose assessment of SeDBP (efficacy cohort). The primary safety population for the assessment of adverse events was defined as study participants who took at least 1 dose of study medication at or beyond the week 4 visit (first-week participants randomized to triple-combination treatment actually received this treatment \[safety cohort\]).

The efficacy of triple- versus each dual-combination treatment in reducing SeBP within age subgroups was assessed using two-sided p-values derived from an analysis of covariance (ANCOVA) model that had baseline BP as a covariate and final randomized treatment, subgroup, and final randomized treatment by subgroup interaction as fixed effects. The LS mean difference and standard error (SE) derived from the ANCOVA model were used to calculate the baseline change in SeBP at week 12. The proportion of study participants reaching BP goal and target by treatment within age subgroups was summarized and analyzed using the chi-square test. The efficacy of triple-combination treatment versus each dual-combination treatment in reaching BP goal and target with age subgroups was assessed using Fisher's exact test at a 0.05 significance level. To account for potential missing data during the double-blind treatment period, each of these analyses used a last observation carried forward (LOCF) approach.

The TRINITY study was powered to assess treatment efficacy in the overall study population. Sample size was determined assuming 97 % power for each of the 3 pairwise comparisons of interest so that a desired overall power of 90 % could be achieved. The study was not powered to assess efficacy between age subgroups. In addition, there was a small number of study participants in the ≥75 years of age subgroup (79 \[3.2 %\]) who were included in the ≥65 years of age subgroup. In the ≥75 years of age subgroup, there were only 25, 19, 17, and 18 participants receiving OM 40/AML 10 mg, OM 40/HCTZ 25 mg, AML 10/HCTZ 25 mg, and OM 40/AML 10/HCTZ 25 mg, respectively. For these reasons, the evaluation of the ≥75 years of age subgroup was for observational purposes, and summary data without statistical comparison are presented.

Results {#Sec8}
=======

Study Population {#Sec9}
----------------

Of the 2492 study participants randomized in the TRINITY study (total cohort), 2021 (81.1 %) were \<65 years of age and 471 (18.9 %) were ≥65 years of age, including 79 (3.2 %) who were ≥75 years of age. Mean ages in the ≥65 and \<65 years of age subgroups were 70.5 (minimum: 65, maximum: 92 years) and 51.5 (minimum: 20, maximum: 64 years), respectively. Both subgroups had a similar prevalence of male participants (≥65 years of age: 51.2 %; \<65 years of age: 53.3 %). However, study participants ≥65 years of age had a greater prevalence of diabetes than study participants \<65 years of age (21.4 vs. 14.2 %, respectively), a lower mean body mass index (31.3 vs. 33.5 kg/m^2^), a longer mean duration of hypertension (14.4 vs. 8.9 years), a greater mean SeSBP (173.5 vs. 167.3 mmHg), a lower mean SeDBP (96.6 vs. 102.0 mmHg), and a greater prevalence of severe hypertension (30.6 vs. 24.1 %) at baseline. Mean SeBP at baseline was similar in the ≥75 and ≥65 years of age subgroups (174.5/94.7 and 173.5/96.6 mmHg, respectively) and the prevalence of severe hypertension was 34.2 % in the ≥75 years of age subgroup and 30.6 % in the ≥65 years of age subgroup.

Table [1](#Tab1){ref-type="table"} summarizes demographic and clinical characteristics at baseline by randomized treatment assignment for each age subgroup.Table 1Baseline demographics by treatment and ageVariableOM 40/AML 10 mgOM 40/HCTZ 25 mgAML 10/HCTZ 25 mgOM 40/AML 10/HCTZ 25 mg\<65≥65≥75\<65≥65≥75\<65≥65≥75\<65≥65≥75N5081202550513219504961750412318Male, n (%)266 (52.4)59 (49.2)11 (44.0)268 (53.1)71 (53.8)8 (42.1)280 (55.6)54 (56.3)8 (47.1)263 (52.2)57 (46.3)7 (38.9)Ethnicity, n (%) Hispanic or Latino76 (15.0)14 (11.7)4 (16.0)68 (13.5)17 (12.9)2 (10.5)79 (15.7)19 (19.8)2 (11.8)77 (15.3)19 (15.4)2 (11.1)Race, n (%)^a^ White329 (64.8)103 (85.8)23 (92.0)320 (63.4)102 (77.3)18 (94.7)317 (62.9)78 (81.3)15 (88.2)312 (61.9)103 (83.7)16 (88.9) Black167 (32.9)14 (11.7)1 (4.0)172 (34.1)28 (21.2)1 (5.3)176 (34.9)16 (16.7)1 (5.9)165 (32.7)19 (15.4)2 (11.1) Asian12 (2.4)1 (0.8)1 (4.0)9 (1.8)1 (0.8)07 (1.4)0018 (3.6)1 (0.8)0 Other1 (0.2)2 (1.7)05 (1.0)1 (0.8)07 (1.4)3 (3.1)1 (5.9)9 (1.8)00BMI, mean (SD), kg/m^2^33.6 (7.5)31.1 (6.0)28.6 (4.8)33.7 (7.5)31.1 (5.6)28.7 (6.3)33.4 (7.3)30.8 (5.2)31.3 (6.7)33.5 (6.9)32.0 (7.3)29.1 (6.9)Obesity (BMI ≥30 kg/m^2^), n (%)336 (66.1)63 (52.5)8 (32.0)323 (64.0)76 (57.6)7 (36.8)322 (63.9)48 (50.0)10 (58.8)327 (64.9)60 (48.8)5 (27.8)Diabetes, n (%)71 (14.0)29 (24.2)5 (20.0)69 (13.7)30 (22.7)4 (21.1)77 (15.3)15 (15.6)5 (29.4)69 (13.7)27 (22.0)3 (16.7)Cardiovascular disease, n (%)36 (7.1)20 (16.7)7 (28.0)43 (8.5)18 (13.6)5 (26.3)39 (7.7)16 (16.7)2 (11.8)38 (7.5)17 (13.8)4 (22.2)Chronic renal disease, n (%)4 (0.8)25 (20.8)11 (44.0)8 (1.6)17 (12.9)9 (47.4)10 (2.0)19 (19.8)8 (47.1)7 (1.4)13 (10.6)4 (22.2)Duration of hypertension, mean (SD), years8.6 (8.2)16.5 (13.2)19.5 (16.4)9.4 (8.9)13.9 (12.3)16.8 (16.9)9.1 (8.4)13.0 (11.1)18.0 (9.3)8.4 (8.7)14.2 (11.4)14.9 (12.2)Baseline SeSBP, mean (SD), mmHg^b^166.7 (13.1)174.2 (13.6)176.0 (14.4)167.4 (15.1)175.0 (12.8)177.2 (12.3)168.3 (14.7)172.1 (12.7)172.2 (14.4)166.7 (13.4)172.5 (12.4)171.8 (14.7)Baseline SeDBP, mean (SD), mmHg^b^102.0 (7.7)96.5 (6.8)94.9 (9.3)101.9 (8.0)96.0 (7.4)95.5 (8.0)102.2 (7.5)96.5 (6.0)95.6 (6.3)101.9 (7.3)97.2 (6.6)92.9 (5.9)Severe hypertension n (%)118 (23.2)42 (35.0)8 (32.0)118 (23.4)42 (31.8)7 (36.8)139 (27.6)29 (30.2)6 (35.3)105 (20.8)31 (25.2)6 (33.3) Baseline SeSBP, mean (SD), mmHg^b,c^181.1 (13.2)188.1 (9.9)190.9 (11.1)186.6 (13.4)189.2 (7.2)189.7 (7.7)184.2 (13.3)186.4 (10.3)187.0 (8.3)184.2 (12.4)188.4 (9.1)187.6 (4.0) Baseline SeDBP, mean (SD), mmHg^b,c^109.6 (9.2)99.5 (7.4)100.5 (11.3)109.5 (9.4)98.9 (7.3)96.0 (9.0)108.4 (8.6)98.6 (7.1)96.2 (7.4)108.4 (9.7)99.1 (8.4)91.0 (6.9)^a^Participants were permitted to select more than 1 race^b^Baseline SeSBP and SeDBP are defined as the mean of randomization visit and the visit immediately preceding randomization^c^Mean blood pressure data in participants with severe hypertension are for efficacy population onlyAML = amlodipine besylate; BMI = body mass index; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomil; SD = standard deviation; SeDBP = seated diastolic blood pressure; SeSBP = seated systolic blood pressure

Efficacy {#Sec10}
--------

Regardless of age, all 4 treatments resulted in significant reductions from baseline in SeDBP and SeSBP at week 12 (LOCF; Fig. [1](#Fig1){ref-type="fig"}). Triple-combination treatment with OM 40/AML 10/HCTZ 25 mg resulted in significantly greater SeBP reductions than any of the dual-combination treatments in both the \<65 and ≥65 years of age subgroups. The efficacy of all 4 treatments in the ≥75 years of age subgroup appeared comparable to the efficacy in the ≥65 years of age subgroup as a whole. Overall, the LS mean reduction in SeBP at week 12 with triple-combination treatment was approximately 38/21 mmHg in study participants \<65 years of age (p \< 0.0001 vs. each dual-combination treatment), approximately 39/24 mmHg in study participants ≥65 years of age (p ≤ 0.002 vs. each dual-combination treatment), and approximately 40/26 mmHg in study participants ≥75 years of age. In each age subgroup, the efficacy of triple- versus dual-combination treatment was typically present within 2 weeks (week 6) of initiating OM 40/AML 10/HCTZ 25 mg (week 4), and was maintained throughout the remainder of the double-blind treatment period (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Least squares (LS) mean reductions in seated diastolic blood pressure (SeDBP; primary efficacy variable) and seated systolic blood pressure (SeSBP) at week 12 (last observation carried forward) by treatment and age. *Error bars* depict standard error (SE) of BP change. \*p \< 0.0001 vs baseline; ^†^p \< 0.0001 vs each dual-combination treatment within age subgroup; ^‡^p = 0.002 vs OM 40/AML 10 mg treatment within age subgroup; ^§^p \< 0.0001 vs OM 40/HCTZ 25 mg and AML 10/HCTZ 25 mg treatments within age subgroup. AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomilFig. 2Mean seated systolic blood pressure (SeSBP; **a**) and seated diastolic blood pressure (SeDBP; **b**) from baseline to week 12 by treatment and age. Week 4 is the first week of triple-combination treatment. Prior to week 4, study participants randomized to triple-combination treatment received 1 of 3 dual-combination regimens. AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomil

As a result, triple-combination treatment was significantly more effective than the component dual-combination treatments in enabling study participants \<65 and ≥65 years of age to reach BP goal (\<140/90 or \<130/80 mmHg in study participants with diabetes, chronic kidney disease, or chronic cardiovascular disease) at week 12 (LOCF), and numerically similar findings were seen in the ≥75 years of age subgroup (Fig. [3](#Fig3){ref-type="fig"}). Overall, approximately 65, 63, and 56 % of study participants randomized to triple-combination treatment in the \<65, ≥65, and ≥75 years of age subgroups, respectively, reached BP goal at week 12 (Fig. [3](#Fig3){ref-type="fig"}). Likewise, triple-combination treatment was more effective than the component dual-combination treatments in achieving the BP target of \<140/90 mmHg at week 12 (LOCF) in all 3 age subgroups (Fig. [4](#Fig4){ref-type="fig"}; post hoc analysis).Fig. 3Proportion of study participants reaching blood pressure (BP) goal (\<140/90 mmHg \[\<130/80 mmHg in study participants with diabetes, chronic kidney disease, or chronic cardiovascular disease\]) at week 12 (last observation carried forward) by treatment and age. \*p \< 0.0001, ^†^p ≤ 0.0004 vs each dual-combination treatment within age subgroup. AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomilFig. 4Proportion of study participants achieving blood pressure (BP) target (\<140/90 mmHg) at week 12 (last observation carried forward) by treatment and age (post hoc analysis). \*p \< 0.0001, ^†^p \< 0.005 vs each dual-combination treatment within age subgroup. AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomil

The efficacy of triple- versus dual-combination treatment appeared to be maintained across age subgroups in the subset of study participants with severe hypertension (SeSBP ≥180 mmHg or SeDBP ≥110 mmHg). In this subset, mean SeBP at week 12 (LOCF) in study participants randomized to triple-combination treatment in the \<65, ≥65, and ≥75 years of age subgroups was reduced approximately 47/24, 50/23, and 47/21 mmHg, respectively, compared with mean reductions of 36--38/18--21, 38--41/16--18, and 36--43/17--22 mmHg in study participants randomized to dual-combination treatments in the same age subgroups (Fig. [5](#Fig5){ref-type="fig"}; post hoc analysis).Fig. 5Mean reductions in blood pressure (BP) at week 12 (last observation carried forward) by treatment and age in study participants with severe hypertension at baseline (post hoc analysis). Severe hypertension was defined as seated systolic BP (SeSBP) ≥180 mmHg or seated diastolic BP (SeDBP) ≥110 mmHg. AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM = olmesartan medoxomil; SD = standard deviation

An ad hoc analysis was performed to determine if there was a trend toward BP reduction using age as a continuous covariate. A linear regression analysis for change in BP from baseline to the end of the 12-week treatment period demonstrated statistical significance (*p* \< 0.05) for triple-combination therapy for both SeDBP and SeSBP. The only other combination therapy which demonstrated a similar pharmacodynamic effect for BP reduction was the dual combination of AML 10/HCTZ 25 mg.

Safety {#Sec11}
------

Triple- and dual-combination treatments were safe and well tolerated across age subgroups and no new safety concerns were identified that were not known to occur with the individual component therapies (Table [2](#Tab2){ref-type="table"}). Overall, 1034 (55.6 %), 253 (57.1 %), and 36 (50.7 %) study participants in the \<65, ≥65, and ≥75 years of age subgroups, respectively, had a treatment-emergent adverse event (TEAE) and 474 (25.5 %), 111 (25.1 %), and 17 (23.9 %) study participants in these same age subgroups had a drug-related TEAE. Most of these adverse events were considered mild or moderate in severity across both treatment and age subgroups. Serious adverse events occurred in 22 (1.2 %), 13 (2.9 %), and 1 (1.4 %) study participant(s) in the \<65, ≥65, and ≥75 years of age subgroups, respectively, and 40 (2.2 %), 13 (2.9 %), and 3 (4.2 %) study participants in these same age subgroups discontinued their study medication due to an adverse event.Table 2Study participants with TEAEs by treatment and age^a^TEAEs, n (%)^b^OM 40/AML 10 mgOM 40/HCTZ 25 mgAML 10/HCTZ 25 mgOM 40/AML 10/HCTZ 25 mg\<65 (n = 483)≥65 (n = 113)\<65 (n = 457)≥65 (n = 123)\<65 (n = 463)≥65 (n = 89)\<65 (n = 456)≥65 (n = 118)ALL TEAEs250 (51.8)58 (51.3)254 (55.6)65 (52.8)267 (57.7)58 (65.2)263 (57.7)72 (61.0)Drug-related TEAEs^c^116 (24.0)22 (19.5)97 (21.2)24 (19.5)135 (29.2)29 (32.6)126 (27.6)36 (30.5)Discontinuations TEAEs5 (1.0)1 (0.9)9 (2.0)3 (2.4)7 (1.5)4 (4.5)18 (3.9)5 (4.2) Drug-related TEAEs3 (0.6)1 (0.9)4 (0.9)1 (0.8)3 (0.6)2 (2.2)16 (3.5)2 (1.7)TEAEs (≥3 % in any treatment group) Dizziness24 (5.0)5 (4.4)47 (10.3)11 (8.9)14 (3.0)3 (3.4)48 (10.5)9 (7.6) Headache34 (7.0)8 (7.1)30 (6.6)8 (6.5)27 (5.8)6 (6.7)28 (6.1)9 (7.6) Upper respiratory tract infection19 (3.9)7 (6.2)16 (3.5)2 (1.6)12 (2.6)2 (2.2)13 (2.9)3 (2.5) Edema peripheral34 (7.0)8 (7.1)4 (0.9)2 (1.6)36 (7.8)10 (11.2)29 (6.4)15 (12.7) Fatigue30 (6.2)4 (3.5)25 (5.5)6 (4.9)29 (6.3)7 (7.9)18 (3.9)6 (5.1) Nausea9 (1.9)3 (2.7)18 (3.9)4 (3.3)11 (2.4)1 (1.1)14 (3.1)3 (2.5) Hypokalemia1 (0.2)1 (0.9)3 (0.7)023 (5.0)2 (2.2)3 (0.7)1 (0.8) Urinary tract infection7 (1.4)1 (0.9)5 (1.1)1 (0.8)6 (1.3)1 (1.1)7 (1.5)7 (5.9) Arthralgia8 (1.7)4 (3.5)9 (2.0)2 (1.6)9 (1.9)3 (3.4)8 (1.8)0 Joint swelling11 (2.3)6 (5.3)1 (0.2)1 (0.8)12 (2.6)4 (4.5)3 (0.7)9 (7.6) Constipation4 (0.8)2 (1.8)3 (0.7)3 (2.4)12 (2.6)05 (1.1)5 (4.2) Diarrhea9 (1.9)5 (4.4)10 (2.2)2 (1.6)8 (1.7)1 (1.1)10 (2.2)5 (4.2) Nasopharyngitis10 (2.1)1 (0.9)15 (3.3)5 (4.1)13 (2.8)3 (3.4)17 (3.7)3 (2.5) Muscle spasms8 (1.7)4 (3.5)11 (2.4)3 (2.4)11 (2.4)2 (2.2)17 (3.7)1 (0.8) Paraesthesia8 (1.7)1 (0.9)8 (1.8)06 (1.3)3 (3.4)4 (0.9)0 Dry mouth4 (0.8)1 (0.9)6 (1.3)2 (1.6)7 (1.5)3 (3.4)3 (0.7)2 (1.7) Blood glucose increased1 (0.2)2 (1.8)01 (0.8)6 (1.3)3 (3.4)1 (0.2)0 Blood potassium decreased1 (0.2)03 (0.7)010 (2.2)4 (4.5)5 (1.1)0 Rash4 (0.8)4 (3.5)4 (0.9)1 (0.8)6 (1.3)2 (2.2)3 (0.7)2 (1.7)Other TEAEs Cough7 (1.4)012 (2.6)3 (2.4)9 (1.9)2 (2.2)8 (1.8)3 (2.5) Hypotension002 (0.4)1 (0.8)006 (1.3)2 (1.7) Orthostatic hypotension001 (0.2)0002 (0.4)0 Vertigo2 (0.4)01 (0.2)001 (1.1)2 (0.4)1 (0.8) Fall1 (0.2)02 (0.4)1 (0.8)2 (0.4)1 (1.1)1 (0.2)1 (0.8)^a^Due to the disproportionate sizes of the age groups and because the ≥75 years of age group is included in the ≥65 years of age group, only TEAEs ≥3 % for the \<65 years of age and ≥65 years of age groups are shown^b^TEAEs were adverse events that emerged during treatment, having been absent pre-treatment or worsened relative to the pre-treatment state. TEAEs are defined as having a start date on or after the first dose of double-blind medication^c^Drug-related was defined as definitely, probably, or possibly related to randomized study medicationAML = amlodipine besylate; HCTZ = hydrochlorothiazide; NR = not reported; OM = olmesartan medoxomil; TEAE = treatment-emergent adverse event

TEAEs occurring in ≥3 % of study participants on any treatment regimen in the \<65 or ≥65 years of age subgroups are listed in Table [2](#Tab2){ref-type="table"}. The most common TEAEs (≥5 % in any treatment group) were dizziness (7.2 %), headache (6.4 %), peripheral edema (5.5 %), and fatigue (5.5 %) in the \<65 years of age subgroup; peripheral edema (7.9 %), headache (7.0 %), dizziness (6.3 %), and fatigue (5.2 %) in the ≥65 years of age subgroup; and peripheral edema (8.5 %), joint swelling (7.0 %), upper respiratory tract infection (5.6 %), and dizziness (5.6 %) in the ≥75 years of age subgroup. However, in the ≥75 years of age subgroup, no more than 3 participants experienced 1 of these TEAEs on any treatment regimen. In particular, the incidence of hypotension (\<65 years of age: 0.4 %; ≥65 years of age: 0.7 %), vertigo (\<65 years of age: 0.3 %; ≥65 years of age: 0.5 %), and falls (\<65 years of age: 0.3 %; ≥65 years of age: 0.7 %) were low across age subgroups for all treatment regimens. Orthostatic hypotension was experienced in 0.2 % of participants who were \<65 years of age and was not reported in any participant ≥65 years of age in any treatment group.

There were no clinically relevant differences in the incidence of TEAEs between study participants \<65 and ≥65 years receiving triple-combination treatment. Although the number of participants in the ≥75 years of age subgroup who were receiving triple-combination treatment was small (n = 16), there did not appear to be any clinically relevant differences in the incidence of TEAEs between this age subgroup (overall incidence: 56 %) and the other age subgroups.

Discussion {#Sec12}
==========

This prespecified subgroup analysis of the TRINITY study demonstrated the efficacy and safety of triple-combination OM 40/AML 10/HCTZ 25 mg treatment in elderly participants with hypertension. Compared with the component dual-combination treatments, triple-combination treatment with OM/AML/HCTZ resulted in greater mean reductions in BP and enabled a larger proportion of study participants to achieve BP goals in all 3 age subgroups. All treatments were well tolerated. The largest BP reductions observed in this evaluation occurred in the very elderly (≥75 years of age) in participants receiving OM 40/AML 10/HCTZ 25 mg (n = 18). This subgroup was a subset of the ≥65 years of age subgroup, which may have contributed to the demonstrated efficacy. The ≥75 years of age subgroup also had the highest absolute rates of cardiovascular disease in patients receiving OM 40/AML 10/HCTZ 25 mg. The potential impact of these observations is substantial because epidemiologic data suggest that a reduction in SBP of 20 mmHg or DBP of 10 mmHg has the potential to reduce adverse events by as much as 50 % \[[@CR6]\]. The favorable benefits observed in outcome trials have resulted in current guidance that hypertension should be treated vigorously in all patients, regardless of age \[[@CR2]\]. In general, those with the best BP control also have the best outcomes. Thus, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a BP goal of \<140/90 mmHg (\<130/80 mmHg in patients with diabetes or chronic kidney disease), regardless of age \[[@CR2]\].

Numerous clinical trials have established the benefits of hypertension treatment in these patients \[[@CR13]--[@CR24]\]. In the 1980s, the European Working Party on High Blood Pressure in the Elderly (EWPHE) demonstrated in a randomized, double-blind, placebo-controlled study that treating hypertension in participants ≥60 years of age significantly reduced cardiac (38 %, p = 0.036) and cardiovascular (27 %, p = 0.037) mortality \[[@CR13]\]. More recently, the Hypertension in the Very Elderly Trial (HYVET) demonstrated that treating hypertension in participants ≥80 years of age to SBP values \<150 mmHg reduced heart failure by 64 % (p \< 0.001), stroke mortality by 39 % (p = 0.046), cardiovascular mortality by 23 % (p = 0.06), and all-cause mortality by 21 % (p = 0.02) \[[@CR20]\]. Consistent with these findings, a meta-analysis of data from 15 trials found that treating hypertension in participants ≥60 years of age significantly reduced all-cause mortality (risk ratio \[RR\]: 0.90; 95 % confidence interval \[CI\]: 0.84--0.97), cardiovascular mortality (RR: 0.77; 95 % CI: 0.68--0.86), coronary heart disease mortality (RR: 0.77; 95 % CI: 0.65--0.90), and cerebrovascular mortality (RR: 0.66; 95 % CI: 0.53--0.82) \[[@CR21]\].

Combination therapy is an attractive approach \[[@CR2]\]. Successfully applying advanced BP goals in elderly patients remains challenging \[[@CR1], [@CR2]\]: only about 20 % of these patients achieve the recommended BP targets \[[@CR2]\]. In hypertension, the etiology of BP elevation is usually multifactorial, making it unlikely that BP control can be achieved by modulating a single mechanism \[[@CR4], [@CR25]\]. The JNC 7 guidelines state that most patients with hypertension require 2 or more antihypertensive medications to achieve BP goal but overall, at least 75 % of patients with hypertension will require at least 2 agents and at least 25 % need at least 3 agents to achieve BP goal (these percentages represent data from a controlled environment of a clinical trial and findings cannot be extrapolated to the general population) \[[@CR2], [@CR7], [@CR25]--[@CR29]\]. In the Study on Cognition and Prognosis in the Elderly (SCOPE), 49 % of participants randomized to active treatment were receiving at least 3 antihypertensive agents by study end \[[@CR7]\]. Similarly, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), 78 % of participants with hypertension and ≥3 other cardiovascular risk factors were receiving at least 2 and 61 % at least 3 antihypertensive agents by study end; addition of a third antihypertensive agent resulted in approximately 30 % of participants with previously uncontrolled hypertension achieving BP goal (\<140/90 mmHg \[\<130/80 mmHg in participants with diabetes\]) \[[@CR30], [@CR31]\]. Thus, the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 2011 Expert Consensus Document on Hypertension in the Elderly recommends adding a third drug from another class if the antihypertensive response is inadequate compared to full doses of 2 drugs from different classes \[[@CR4]\].

BP control in the elderly is also complicated by adverse events, such as hypotension, and drug interactions \[[@CR4]\]. Elderly patients are also more likely to have end organ damage that may influence drug selection and response to therapy \[[@CR2], [@CR4]\]. In addition, pathophysiologic, lifestyle, and treatment-related factors in these patients may adversely affect compliance with any antihypertensive therapeutic regimen \[[@CR4]\].

In the present study, triple-combination treatment was well tolerated in participants \<65 and ≥65 years of age, with a similar prevalence of TEAEs (57.7 and 61.0 %), drug-related TEAEs (27.6 and 30.5 %), and study drug discontinuations due to a TEAE (3.9 and 4.2 %). The incidence of hypotension was similar across age groups (\<65 years of age: 0.4 %; ≥65 years of age: 0.7 %); however, more participants ≥75 years of age (4.2 %) discontinued their study medication due to an adverse event compared with participants \<65 years of age (2.2 %) and ≥65 years of age (2.9 %). OM either as monotherapy or in combination with HCTZ and/or AML is an effective and safe treatment for hypertension in a broad range of patients, including the elderly \[[@CR32]--[@CR36]\]. In one study, 52--67 % of study participants ≥65 years of age receiving OM/HCTZ combination therapy achieved the SeBP goal of \<140/90 mmHg, while in another study, 61 % of participants ≥65 years of age receiving OM/AML combination therapy, with or without HCTZ, achieved the SeBP goal of \<140/90 mmHg (\<130/80 mmHg in participants with diabetes) \[[@CR32], [@CR34]\]. In patients with diabetes, chronic kidney disease, or chronic cardiovascular disease, short-term (12 weeks) and long-term treatment with OM 40/AML 10/HCTZ 25 mg was well tolerated, lowered BP more effectively, and enabled more participants to reach BP goal than the corresponding dual-combination therapies \[[@CR37]\]. Furthermore, in another multinational, phase 3 study, adding HCTZ to a range of OM/AML dose combinations was well tolerated and improved BP control by significantly lowering BP in patients with moderate-to-severe hypertension \[[@CR38]\].

A critical factor in achieving benefit is adherence to therapy, which has been shown to correlate inversely with the number of pills in a therapeutic regimen \[[@CR8], [@CR9], [@CR39]\]. Nonadherence is a major contributing factor to inadequate BP control \[[@CR40]--[@CR42]\] and can be particularly problematic in elderly individuals taking polypharmacotherapy (often with 6 or more medications) for multiple comorbidities \[[@CR4]\]. The ACC/AHA 2011 Expert Consensus states that potential benefits of single-pill combination therapy include increased efficacy, reduced adverse events, and additive target organ protection \[[@CR4]\]. Furthermore, by decreasing the number of copayments required, this therapy could reduce out-of-pocket costs, an important consideration in the elderly due to lower incomes \[[@CR4], [@CR43]\]. Thus, single-pill combination therapy provides a convenient and effective option for many patients that may increase adherence and persistence \[[@CR44]--[@CR49]\].

Certain limitations exist in this study. While the evaluation of the elderly (≥75 years of age and ≥65 years of age) and non-elderly subgroups (\<65 years of age) was pre-defined, statistical analyses between these subgroups was not completed because of the unequal participant numbers in the subgroups. Achieved SeBP reductions were comparable with treatment cohorts and the age subgroups and did not warrant further analyses between subgroups. Participants with various illnesses, including active heart disease and poorly controlled diabetes (i.e., HbA~1c~ \>9 %), were excluded from participation; therefore, caution must be exercised regarding generalizability of these data to the overall population. In addition, the TRINITY study evaluated only a single dose for each agent used and therefore does not provide information on the efficacy or safety of these regimens using different dosing schemes. Also, in clinical practice, patients are likely to be titrated from no drugs to 1 drug, 2 drugs, and then a regimen with 3 drugs. While the TRINITY 12-week study is not designed in this way, it is reasonable to assume that if patients were titrated in the study as they are in clinical practice, the total BP reduction would be similar.

Conclusions {#Sec13}
===========

This prespecified subgroup analysis of the TRINITY study demonstrated that OM 40/AML 10/HCTZ 25 mg triple-combination treatment was both safe and effective in study participants with hypertension, regardless of age. Triple-combination treatment resulted in greater reductions in SeSBP and SeDBP and, as a result, was more effective in enabling study participants to reach BP goal compared with the component dual-combination treatments in all age subgroups. Triple-combination treatment was well tolerated, with low prevalences of hypotension and few discontinuations due to drug-related TEAEs in both the \<65 and ≥65 years of age subgroups. Triple-combination treatment with OM 40/AML 10/HCTZ 25 mg may provide a safe and effective treatment option for elderly patients whose BP is not adequately controlled with dual-combination treatment. Other combinations of similar classes of medications may be efficacious at reducing BP, but will need to be evaluated.
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